03:48:25 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2023-11-10 Kvartalsrapport 2023-Q3
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-17 Årsstämma 2023
2023-05-05 Kvartalsrapport 2023-Q1
2023-02-24 Bokslutskommuniké 2022
2022-11-29 Extra Bolagsstämma 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning ALZCUR 0.00 SEK
2022-05-17 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-24 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-18 Ordinarie utdelning ALZCUR 0.00 SEK
2021-05-17 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-26 Bokslutskommuniké 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-25 Kvartalsrapport 2020-Q2
2020-05-22 Ordinarie utdelning ALZCUR 0.00 SEK
2020-05-20 Årsstämma 2020
2020-04-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-15 Kvartalsrapport 2019-Q3
2019-08-31 Kvartalsrapport 2019-Q2
2019-05-23 Ordinarie utdelning ALZCUR 0.00 SEK
2019-05-22 Årsstämma 2019
2019-05-01 Kvartalsrapport 2019-Q1
2019-02-28 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
AlzeCure Pharma är ett läkemedelsbolag. Bolaget är inriktade mot forskning och utveckling av läkemedel som används för diverse hjärnsjukdomar, med störst fokus mot Alzheimers sjukdom. Teknologin och forskningen utgår ifrån egen läkemedelsplattform, där bolaget utvecklar olika symptomlindrande läkemedelskandidater. Huvudkontoret ligger i Huddinge.
2022-08-16 08:00:00

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that Drug Discovery Today has published a new review article on the biological mechanism underlying AlzeCure’s NeuroRestore platform and its leading drug candidate ACD856.

The publication, titled “Neurotrophin targeted therapeutics – a gateway to cognition and more?”, was published in Drug Discovery Today and written by Dr. Gunnar Nordvall, Head of Chemistry, Dr. Pontus Forsell, Head of Research and Discovery and Dr. Johan Sandin, CSO at AlzeCure.

The article focuses on the growing interest and developments in the area of neurotrophins, such as nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF), as novel cognitive enhancing therapies for different disorders including Alzheimer’s disease. The development of AlzeCure’s NeuroRestore platform with its leading clinical drug candidate ACD856, is also discussed as a recent example of this. AlzeCure has recently completed two clinical phase I studies with ACD856 which is being developed with a focus on Alzheimer's disease.

"This publication shows the multiple exciting opportunities that exist for ACD856, which targets these significant biological signaling mechanisms. These include memory-enhancing effects in diseases with cognitive impairment, such as Alzheimer's, but also potential for disease modifying, neuroprotective effects," said Johan Sandin, CSO of AlzeCure Pharma AB.

“There is increasing international scientific interest in this area to develop drugs with novel mechanisms and the neurotrophin area is a highly interesting one with potential for multiple indications, not only Alzheimer’s but also depression and Parkinson’s are disorders where this mechanism has scientific support," said Martin Jönsson, CEO of AlzeCure Pharma AB.

The article is now available online as an Open access article and can be found at: https://doi.org/10.1016/j.drudis.2022.07.003.